NKGN VS NVNO Stock Comparison

Performance

NKGN
10/100

NKGN returned -53.87% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

NVNO
10/100

NVNO returned -21.56% in the last 12 months. Based on SPY's performance of -13.88%, its performance is below average giving it a score of 10 of 100.

Volatility

NKGN
10/100

NKGN has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.

NVNO
45/100

NVNO has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Technicals

NKGN

"Technicals" not found for NKGN

NVNO
57/100

NVNO receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

Earnings

NKGN

"Earnings" not found for NKGN

NVNO
10/100

NVNO has missed earnings 10 times in the last 20 quarters.

Profit

NKGN

"Profit" not found for NKGN

NVNO
10/100

Out of the last 20 quarters, NVNO has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

NKGen Biotech, Inc. Common Stock Summary

Nasdaq / NKGN

Healthcare

Biotechnology

Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.

enVVeno Medical Corporation Common Stock Summary

Nasdaq / NVNO

Healthcare

Medical - Devices

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Power up your portfolio